Subsequently, a growing body of research has identified that aberrant SNHG20 expression definitely interacted with prognostic outcomes and clinicopathological characteristics in patients with many kinds of malignancies, including bladder cancer [9], osteosarcoma [10], glioma [11], colorectal cancer [12], gastric cancer [13], lung cancer [14], cervical cancer [15], esophageal carcinoma [16], oral carcinoma [17], nasopharyngeal carcinoma [18], ovarian cancer [19], and laryngeal carcinoma [20]. Here, SNHG20 is linked to nasopharyngeal carcinoma.